The GarMiglio Lab (https://t.co/hIMbmNmEmH) is looking for talented researchers to develop computational pipelines to integrate multiomics data aimed to dissect the molecular mechanisms of cancer progression, metastasis and resistance to therapy. Check👇
https://t.co/tlLtjm1ACn
Spatial homotypic cell clustering (tumor cells as white flowers) preserves cell identity while dispersion (carnivorous plants) promotes cancer cell plasticity and aggressiveness. https://t.co/3SIL92NUgW
Thank you to Cancer Cell editorial to make this happens.
@JustinLathia@SylvesterCancer Such an amazing and inspiring visit! Great opportunity to network with great scientists over there! Thank you Justin for inviting me :)
In our paper, through innovative computational tools, we found that @glioblastoma cell states co-localize with specific TME components and that spatial clustering preserves tumor cell identity, while dispersion promotes plasticity.
https://t.co/3SIL92NUgW
#AACR24 is unique because you meet amazing people, and you meet on person people you always work with virtually and then everything becomes MAGIC and INSPIRING.
Thanks for this opportunity.
Strana l'informazione sulla salute... alle volte i media celebrano scoperte che hanno ricadute pratiche lontane anni luce e snobbano ricerche promettenti prossime ad arrivare al letto del malato.
Un esempio è lo studio da poco pubblicato da @MigliozziSimona del gruppo di ricerca del prof. Iavarone sulle forme resistenti di #glioblastoma, un tumore particolarmente difficile da trattare.
Nell'analisi i ricercatori hanno scoperto uno dei meccanismi che il tumore mette in atto per nascondersi e somigliare ad una normale cellula cerebrale. Ma c'è di più. Dopo aver individuato il responsabile, hanno testato un farmaco a target molecolare (vemurafenib) già in commercio per altri tumori e i risultati nel modello animale sono stati davvero confortanti.
La straordinarietà risiede nel fatto che quel farmaco, oggi, viene somministrato solo in quei tumori che presentano una mutazione nel gene BRAF. Molti glioblastomi, però, non hanno questa caratteristica. Eppure, grazie ad un'analisi proteomica, gli autori dello studio hanno mostrato che il prodotto di quel gene apparentemente normale è particolarmente attivo e per questa ragione può essere sfruttato come bersaglio.
Ora il gruppo di ricerca è al lavoro per cercare di disegnare un trial clinico capace di combinare chemioterapia e inibitori di BRAF nelle persone con glioblastoma.
Lo racconto qui: https://t.co/l2oyddcGKZ
A new platform developed by Dr. Antonio Iavarone and collaborators will offer greater insight into treating #glioblastoma. Learn how this tool will look at #BrainCancer proteins to identify therapies that could kill these resistant cancers. https://t.co/EDL8b3KN4I
Happy to share our work on primary and recurrent #glioblastoma. Multi-omics platforms captured a specialized neuronal program in recurrent GBM. We identified BRAF as a therapeutically actionable target in recurrent GBM. Congrats all for this amazing work!
https://t.co/jlO1wrnc8l
Happy to share the amazing cover page @NatureCancer journal dedicated to our recent work on the reconstruction of tissue-specific kinase-substrate interactome for the identification of master kinases in glioblastoma! Thank you! Check it 👇
https://t.co/DeN5Ve1zxw
💫ONLINE NOW @NatureCancer „Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy” by #AnnaLasorella#AntonioIavarone.
Don't miss it 👇
https://t.co/fdFkwoKIlj
https://t.co/FyEsuUOwm9
SPHINKS, a SVM learning approach integrates proteomics and phospho-proteomics for the reconstruction of a GBM kinase-phosphosite network interactome identifying PKCδ and DNA-PKcs as therapeutically targetable master kinases in #Glioblastoma https://t.co/FE8Aalby7Y
Thanks to the Society for Neuro-Oncology #SNO2022 for conferring me such an ambitious award in Molecular Pathology. It was such a great honor to present my research in the targeting of glioblastoma at the world’s largest neuro-oncology conference. https://t.co/mVrcVAmvki
Check my poster at #AACR2022 on a pathway based and multiomics approach we implemented for stratification of #Glioblastoma tumors! We developed an unbiased protein kinase signaling network approach for the selection of master kinases clinically targetable for #gbm subtypes!
⭐️DON'T MISS our trifecta single-cell studies in #glioblastoma@NatureCancer
- Iavarone & Co:
https://t.co/wkphgQVQK8
- @PughLab &Co:
https://t.co/q18eWpgQ9l
- Piccolo & Co:
https://t.co/Nlf3biO5jg
+a *FAB* NVs by @JustinLathia to discuss them:
https://t.co/kHZFuAj7Xk